New Precision Therapeutics, Inc. Study Supports Potential Utility of ChemoFx in Primary Ovarian Cancer  
11/12/2012 9:36:18 AM

PITTSBURGH--(BUSINESS WIRE)--A new study that looks at the synergy between ChemoFx® in vitro drug response marker results for non-platinum single agents alone and in combination with carboplatin was presented at the International Gynecologic Cancer Society (IGCS) Annual Meeting, which was held in Vancouver October 13-16, 2012. Dr. Dennis Scribner presented the abstract, titled, Does In-Vitro Chemosensitivity Show Synergy When Comparing Single Agents to Platinum-Based Combinations in Ovarian Cancer. The study, performed in cooperation with Virginia Tech Carilion School of Medicine, analyzed primary ovarian cancer specimens for patterns of response to platinum and non-platinum based therapies, using the ChemoFx® Drug Response Marker. The investigation was implemented to observe synergy in drug sensitivity between single agents and combination agents in vitro.